InterCure (INCR) Competitors

Lifecore Biomedical (NASDAQ:LFCR) and InterCure (NASDAQ:INCR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Which has preferable earnings & valuation, LFCR or INCR?

InterCure has lower revenue, but higher earnings than Lifecore Biomedical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	2.15	-$38.72M	-$1.31	-5.66
InterCure	$64.55M	N/A	-$18.32M	N/A	N/A

Do analysts rate LFCR or INCR?

Lifecore Biomedical presently has a consensus price target of $8.00, suggesting a potential upside of 7.82%. Given Lifecore Biomedical's stronger consensus rating and higher probable upside, equities analysts plainly believe Lifecore Biomedical is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
InterCure	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media prefer LFCR or INCR?

In the previous week, Lifecore Biomedical had 2 more articles in the media than InterCure. MarketBeat recorded 5 mentions for Lifecore Biomedical and 3 mentions for InterCure. InterCure's average media sentiment score of 0.29 beat Lifecore Biomedical's score of 0.10 indicating that InterCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InterCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, LFCR or INCR?

Lifecore Biomedical has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, InterCure has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Is LFCR or INCR more profitable?

InterCure has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -31.70%. InterCure's return on equity of 0.00% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-31.70%	-846.51%	-13.03%
InterCure	N/A	N/A	N/A

Do insiders & institutionals hold more shares of LFCR or INCR?

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 32.2% of Lifecore Biomedical shares are owned by insiders. Comparatively, 0.2% of InterCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Lifecore Biomedical beats InterCure on 7 of the 13 factors compared between the two stocks.